ArticleAmerican journal of translational research2021
The impact of asthma-exclusive nursing scheme on the treatment effect of asthma patients.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the impact of the asthma-exclusive nursing scheme on the treatment effect of asthma patients.
methodsA total of 120 asthma patients treated in our hospital from January 2019 to June 2019 were included for the research, with 60 patients in Group A from January 2019 to March 2019, and 60 patients in Group B from April 2019 to June 2019. Montelukast combined with formoterol lyophilized powder was employed as the treatment for all patients. An asthma-exclusive nursing scheme was given to Group A, and conventional nursing was applied to Group B. The analysis and comparison of symptom relief time (SRT), pulmonary function indicators (PFI), 6-minute walking distance (6MWD), adverse drug reactions (ADRs), levels of inflammatory factors (LIF), and overall efficacy between the two groups were conducted.
resultsAfter the treatment, Group A yielded a more promising outcome of SRT than Group B (P<0.001). Moreover, a notable increase of PFI and LIF of both groups of patients was observed, in which Group A garnered more promising results than Group B (P<0.001), and similar results were also demonstrated with regard to 6MWD (P<0.001). Neither abnormal metabolism in patients nor significant difference of ADRs between the two groups was detected (P>0.05). The overall efficacy and compliance rate of Group A were higher than those of Group B, and the 6-month recurrence rate was lower than that of Group B (P<0.05).
conclusionWith the aid of an asthma-exclusive nursing scheme, montelukast combined with formoterol can safely and substantially optimize the PFI and LIF of asthma patients and enhance their exercise capacity, which is of application value in clinical practice.
Indexed as
Identifiers
34540017PMC8430090W3200780793What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.